On a consensus basis, popular market professionals have fixed mean target price of $41.375 for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). This equity call is the mean of 8 brokerages’ calls. Research entities evaluate the financial aspects of a company and then draft their unique reports on an equity.
According to analysts, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is anticipated to announce EPS for the quarter of $-0.65. It is the consensus reached after considering analysts’ posted statistics. For the period ending on 2016-09-30 the EPS was $-0.61.
Average broker recommendation can be stated as the mean of discrete ratings set by sell-side forecasters to know a Consensus Rating. On a base of 1 to 5, where Zacks call 3 as hold call and 1 as Strong Buy call, the stock is ranked 1.75 based on 8 recommendations.
Of the 8 analyst estimates, the optimistic experts view the equity at $60 in the upcoming 12-months. Yet, conservative target is fixed at $25.
In looking at the entity’s progress prospects, mean target EPS for the current year is $-2.37. The high figure divulged in this time frame is $-1.94 with the low being $-2.69.
Analyzing 3-5 years growth pace of EPS, it stands at 15.31%, based on 1 analysts providing forecasts.
Before concluding any investment choice based on analysts call, it is best to review other factors, and not to forget, conflicts of interest. Various street professionals provide specialist services to popular financial groups that underwrite securities. This underwriter team act as an intermediary unit between the company offering equity and investors purchasing the shares. Subsequent to the IPO completion, they can extend alliance with the firm or get a striking sum of the entity’s equity. It will repeatedly gain from market professional calls that would raise the price of, or swell trading in, that equity.